v3.25.1
Segment Information
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Information SEGMENT INFORMATION
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (“CODM”), in deciding how to allocate resources and in assessing performance. The Company and the Company’s chief operating decision maker view the Company’s operations and manage its business in one operating segment, which is the business of identifying, developing and commercializing pharmaceutical products that target unmet needs in women's health. The CODM, who is the chief executive officer (“CEO”), manages and allocates resources to the operations of the Company on a consolidated basis. The Company’s measure of segment profit or loss is net loss. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company’s long-term company-wide strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. Operating expenses are used to monitor budget versus actual results. The CODM does not review assets in evaluating the results of the Company, and therefore, such information is not presented. In addition, substantially all of the Company's revenue was generated in the United States and substantially all of the Company's long-lived assets reside in the United States.

The following table summarizes the segment's financial information including the Company’s significant segment expenses:
Three Months Ended
March 31,
20252024
Revenue:
Royalty revenue$25,427 $9,302 
Total revenue25,427 9,302 
Segment operating expenses:
Research and development:
Direct program costs:
Ovaprene1,495,727 2,183,873 
Sildenafil Cream, 3.6%211,389 460,107 
Other advanced clinical stage programs490,562 446,671 
Phase 1 and Phase 1-ready clinical stage programs496,747 229,550 
Preclinical stage programs1,098,738 1,371,708 
Other development programs— 12,794 
Contra-R&D expenses(2,618,373)(2,652,715)
Total research and development direct program costs1,174,790 2,051,988 
Indirect costs:
Personnel-related (including stock compensation)1,492,248 1,482,597 
Other indirect costs78,735 78,199 
Contra R&D expenses(448,392)(259,264)
Total research and development indirect costs1,122,591 1,301,532 
General and administrative2,309,164 2,670,581 
Other operating expenses— 7,674 
Total segment operating expenses4,606,545 6,031,775 
Loss from operations(4,581,118)(6,022,473)
Interest expense134,050 209,138 
Interest income(156,621)(88,133)
Other income (expense), net180,240 (611,878)
Net loss$(4,378,307)$(6,755,356)